Thompson Davis & Co’s Co-Diagnostics CODX Stock Holding History

Thompson Davis & Co’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,907	Closed	-$42.8K	–	135
2024 Q4	$42.8K	Buy	1,907 +524	+38%	+$16.5K	0.03%	116
2024 Q3	$51.9K	Hold	1,383	–	–	0.04%	112
2024 Q2	$51.9K	Buy	+1,383	New	+$50.3K	0.05%	100

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAG

Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Thompson Davis & Co's CODX Position: Q1 2025 in Review

Thompson Davis & Co sold out of Co-Diagnostics (CODX) in Q1 2025, closing a stake of 1,907 shares — an estimated $42.8K sold.

Thompson Davis & Co first reported a position in CODX in Q2 2024 and held it in 3 quarters. The position peaked at $51.9K in Q3 2024. 38 funds tracked by Wall St. Rank hold CODX as of Q1 2025.

Thompson Davis & Co reported no remaining Co-Diagnostics position as of Q1 2025 after selling out during the quarter.
Thompson Davis & Co sold 1,907 Co-Diagnostics shares in Q1 2025, an estimated $42.8K.
Thompson Davis & Co first reported a position in Co-Diagnostics in Q2 2024 and held it in 3 quarters.
Thompson Davis & Co's Co-Diagnostics position peaked at $51.9K in Q3 2024.
38 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2025.

Based on Thompson Davis & Co's 13F filing for Q1 2025, filed 13 May 2025.